Exicure, Inc. XCUR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Exicure, Inc. (XCUR) is a healthcare company listed in the US with a market value of about $7M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -114%.
About Exicure
Exicure is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2016 to $500000 in 2024, a decline of about 8.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 582% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $500000 | $0 | $29M | -$483000 | $17M | $1M | $118000 | $10M | $1M |
| Net income | -$5M | -$10M | -$17M | -$3M | -$64M | -$25M | -$26M | -$22M | -$11M | -$17M |
| Free cash flow | -$9M | -$3M | -$10M | -$36M | -$36M | -$42M | $235000 | -$20M | -$21M | -$5M |
| EPS (diluted) | $-0.79 | $-4.75 | $-10.55 | $-2.80 | $-108.50 | $-42.00 | $-69.00 | $-81.00 | $-163.50 | $-22405.27 |
| Net margin | — | -1940.2% | — | -9.0% | 13271.6% | -148.5% | -2029.5% | -18994.1% | -113.3% | -1635.2% |
| ROIC | -91.5% | -76.0% | -154.7% | -6.5% | -240.9% | -29.5% | -30.9% | -66.6% | -41.9% | -199.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Exicure pay a dividend?
Not currently.
Is Exicure a good stock to buy?
We do not give buy or sell advice. Exicure scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.